12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Company News  |  Deals

Enzon, Zhejiang Hisun Pharmaceutical deal

Enzon will use its PEGylation Linker Technology to develop PEGylated versions of selected candidates from Hisun. The pharma will have an option to license the therapeutics in China, where it will be responsible for further development and commercialization. Enzon will be eligible for milestone payments and royalties...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >